GlaxoSmithKline (GB:GSK) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
GSK’s latest trial results reveal that Blenrep, in combination with other drugs, significantly reduces the risk of death in multiple myeloma patients by 42% compared to the standard treatment. These findings highlight Blenrep’s potential to become a new standard of care, with regulatory reviews underway in major markets. Investors might find GSK’s advancements in this treatment promising for the company’s growth and stock performance.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
